<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25119">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986114</url>
  </required_header>
  <id_info>
    <org_study_id>D1002002</org_study_id>
    <nct_id>NCT01986114</nct_id>
  </id_info>
  <brief_title>A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.</brief_title>
  <official_title>A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dainippon Sumitomo Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dainippon Sumitomo Pharma</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the long-term efficacy and safety of SM-13496 in patients with bipolar I
      disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120
      mg/day) in patients with bipolar I disorder.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and adverse drug reactions (ADRs)</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) score</measure>
    <time_frame>Baseline, 52 weeks and each month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Young Mania Rating Scale (YMRS) total score.</measure>
    <time_frame>Baseline, 52 weeks and each month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to recurrence/relapse of any mood event from clinical stability of bipolar disorder.</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>SM-13496  20-120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-13496 (lurasidone HCl)</intervention_name>
    <description>SM-13496 20-120mg</description>
    <arm_group_label>SM-13496  20-120mg</arm_group_label>
    <other_name>Lurasidone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who completed the D1002001 study

        ・Patients who completed the D1002001 study and who are considered by the investigator to
        be eligible and without safety concerns.

        Patients who did not participate in the D1002001 study

          -  Patients who were fully informed of and understand the objectives, procedures, and
             possible benefits and risks of the study and who provided written voluntary consent
             to participate in the study.

          -  Outpatients aged 18 through 74 years at the time of consent

          -  Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode manic,
             hypomanic, or mixed (≥ 4 weeks and less than 12 months) without psychotic features.

        Exclusion Criteria:

          -  Patients with imminent risk of suicide or injury to self, others, or property.

          -  Patients who are otherwise considered ineligible for the study by the investigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Dainippon Sumitomo Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dainippon Sumitomo Pharma Co., Ltd.</last_name>
    <email>cc@ds-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>China 5 sites</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japan 60 sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Malaysia 4 sites</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippines 5 sites</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russia 7 sites</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiwan 4 sites</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ukraine 7 sites</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 1, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
